Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Actavis Sells China JV to Zhejiang Chiral Medicine

publication date: Jan 28, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Actavis, the global generic drug company, has agreed to sell its interest in its China JV, Actavis (Foshan) Pharmaceuticals, to Zhejiang Chiral Medicine Chemicals. Two weeks ago, Actavis said China was too risky and the business opportunity too uncertain (see story). According to the company, other countries presented a better risk-reward proposition, and Actavis had decided to pull out of China. However, now Actavis says it intends to continue commercial operations in China, working with “its preferred business partners.” The company did not explain the apparent contradiction. More details....

Stock Symbol: (NYSE: ACT)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...